Collateral damage of the COVID-19 pandemic observed among patients receiving treatment with intravitreal (IVT) injections of antiangiogenic agents FRESH-PEF73553-en Patrick VACHEY Collateral damage of the COVID-19 pandemic observed among patients receiving treatment with intravitreal (IVT) injections of antiangiogenic agents COVIDIV FRESH-PEF73553-en 73553 FRESH-PEF73553 Patrick VACHEY FONDATION A DE ROTHSCHILD Epidemiology France Portal (PEF) null Ophthalmology Peripheral retinal degeneration COVID-19 Describe the changes in visual acuity among patients receiving treatment with repeat IVT injections of antiangiogenic agents during the COVID-19 epidemic, between September 2019 and May 2021 null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Patient aged 18 years and over -Eye disorder requiring treatment with repeat IVT injections of antiangiogenic agents: Exudative ARMD, macular oedema associated with diabetes or secondary to retinal vein occlusion. -Initiation of treatment with repeat IVT injections before 01/10/2019 Clinical data Participant-reported health data Other [1000-10000[ individuals Converting or copying information into a structured record Interview with the participant (including clinical) Observational Study Observational Study 1,500 planned - actual number included: 233 Unknown To be defined